| [1] |
Hospers GA, Helmond FA, de Vries EG, et al. PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des, 2008, 14(28): 3020-3032. doi: 10.2174/138161208786404362
|
| [2] |
Kumar P, Mercer J, Doerkson C, et al. Clinical production, stability studies and PET imaging with 16-alpha-[18F]-fluoroestradiol([18F]-FES) in ER positive breast cancer patients. J Pharm Pharm Sci, 2007, 10(2): 256s-265s.
|
| [3] |
Mortimer JE, Dehdashti F, Siegel BA, et al. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16α-[18F]-17β-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res, 1996, 2(6): 933- 939.
|
| [4] |
Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med, 2005, 35(2): 84-99. doi: 10.1053/j.semnuclmed.2004.11.001
|
| [5] |
Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol, 2006, 24(18): 2793-2799. doi: 10.1200/JCO.2005.04.3810
|
| [6] |
Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res, 2011, 17(14): 4799-4805. doi: 10.1158/1078-0432.CCR-10-3321
|
| [7] |
van Kruchten M, Glaudemans AW, de Vries EF, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med, 2012, 53(2): 182-190.
|
| [8] |
Tsujikawa T, Yoshida Y, Kudo T, et al. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET. J Nucl Med, 2009, 50(10): 1598-1604. doi: 10.2967/jnumed.108.060145
|